Impax's (IPXL) Guidance Disappoints But Excludes Hidden Opportunity - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Impax Laboratories (IPXL) Tops Q4 EPS by 18c
February 22, 2016 6:57 AM ESTImpax Laboratories (NASDAQ: IPXL) reported Q4 EPS of $0.62, $0.18 better than the analyst estimate of $0.44. Revenue for the quarter came in at $282.1 million versus the consensus estimate of $223.23 million.
For earnings history and earnings-related data on Impax Laboratories (IPXL) click here.
... More